P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL) - Daniel Hodson; Geoffrey Shouse; Ho-Jin Shin; Antonio Salar Silvestre; Sabela Bobillo Varela; Vincent Ribrag; Nicol Macpherson; Raul Cordoba; Jin Seok Kim; John Radford; Stephanie Guidez; Alex F. Herrera; et al. (HemaSphere, 2023)